Veraxa Biotech presents in vivo proof — of — concept data for BiTAC — ADC platform at World ADC Congress
Veraxa Biotech AG presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the World ADC Congress. Data showed the dual-component approach drove tumor shrinkage in an animal cancer model following systemic dosing. Non-targeted dosing configurations produced no meaningful anti-tumor effect, supporting a tumor-restricted activation mechanism. Results indicated a differentiated safety profile versus conventional ADC design, with no apparent treatment-related weight loss in the study. Veraxa positioned BiTAC-ADCs as a second R&D pillar alongside its BiTAC-TCE programs, expanding partnering optionality in solid tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via (Ref. ID: 202610130700OMX_____CNEWS_EN_GNW1001277666_en) on October 13, 2026, and is solely responsible for the information contained therein. (C)
Veraxa Biotech AG presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the World ADC Congress. Data showed the dual-component approach drove tumor shrinkage in an animal cancer model following systemic dosing. Non-targeted dosing configurations produced no meaningful anti-tumor effect, supporting a tumor-restricted activation mechanism. Results indicated a differentiated safety profile versus conventional ADC design, with no apparent treatment-related weight loss in the study.
Veraxa positioned BiTAC-ADCs as a second R&D pillar alongside its BiTAC-TCE programs, expanding partnering optionality in solid tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via (Ref.
ID: 202610130700OMX_____CNEWS_EN_GNW1001277666_en) on October 13, 2026, and is solely responsible for the information contained therein. (C)